Mumbai, Feb. 13 -- NATCO Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical

Ingredient Division located in Manali, Chennai from 17 November - 21 November 2025. The Company received seven (7) observation in the Form-483.

Further, the Company has received the EIR (Establishment Inspection

Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI).

Published by HT Digital Content Services with permission from Capital Market....